Vanguard Capital Management’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
Other funds holding PCRX
Vanguard Capital Management's PCRX Position: Q3 2026 in Review
Vanguard Capital Management reduced its Pacira BioSciences (PCRX) stake by 3.8% in Q3 2026, selling an estimated $1.65M and leaving 1,626,585 shares worth $40.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2012.
Vanguard Capital Management first reported a position in PCRX in Q1 2026 and has held it in 3 quarters since. The position peaked at $42.9M in Q2 2026. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.
- Vanguard Capital Management held 1,626,585 shares of Pacira BioSciences worth $40.7M as of Q3 2026.
- Vanguard Capital Management sold 64,986 Pacira BioSciences shares in Q3 2026, an estimated $1.65M.
- Pacira BioSciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #2012 holding.
- Vanguard Capital Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Pacira BioSciences position peaked at $42.9M in Q2 2026.
- 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.